HopeStage
Back to all studies
Recruitment unclearEUCTR 2020-001424-34

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SAGE-217 IN THE TREATMENT OF ADULTS WITH SEVERE POSTPARTUM DEPRESSION

This historical record does not confirm current site availability.

Historical research recordUnited Kingdom
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Who could participate?

This study is for people with depression. Other eligibility criteria apply.

Listed locations
United Kingdom
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Recruitment unclear
Enrollment listed in the registry
192
Sponsor
Sage Therapeutics, Inc.
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United Kingdom
Age range
Not clearly listed
Official registry ID
EUCTR 2020-001424-34
Official title
Show the full official title

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SAGE-217 IN THE TREATMENT OF ADULTS WITH SEVERE POSTPARTUM DEPRESSION

Recruitment & locations

Status unknown

United Kingdom

Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Sage Therapeutics, Inc.

Who can participate?

This study is for people with depression. Other eligibility criteria apply.

Want to explore more studies?

Explore studies